10% Off
Triovix150 mg+300
Beximco Pharmaceuticals Ltd.
৳63.00
Out Of Stock
Generic medicine
Lamivudine + Zidovudine + Nevirapine: Brands, Price & Uses in Bangladesh
Lamivudine + Zidovudine + Nevirapine is a fixed-dose combination (FDC) antiretroviral tablet combining two nucleoside reverse transcriptase inhibitors (NRTIs) with one non-nucleoside reverse…
About Lamivudine + Zidovudine + Nevirapine
Indications of Lamivudine + Zidovudine + Nevirapine
Lamivudine + Zidovudine + Nevirapine is a fixed-dose combination (FDC) antiretroviral tablet combining two nucleoside reverse transcriptase inhibitors (NRTIs) with one non-nucleoside reverse transcriptase inhibitor (NNRTI) in a single tablet, intended to simplify triple-drug antiretroviral therapy (ART).
Established / Guideline-Supported Use
- Treatment of HIV-1 infection: Lamivudine + Zidovudine + Nevirapine is indicated as a complete triple-drug antiretroviral regimen for the treatment of HIV-1 infection in treatment-naive adults and adolescents, used in accordance with WHO and national HIV treatment guidelines, particularly as a first-line regimen in resource-limited settings.
- Pediatric use: corresponding pediatric-strength formulations of the same three-drug combination are used for treatment of HIV-1 infection in children, dosed by body weight per national/WHO pediatric ART guidelines (see Use in Special Populations).
Important Notes
- Lamivudine + Zidovudine + Nevirapine must always be used as part of a complete, guideline-directed regimen and must never be used as monotherapy with only one component.
- Lamivudine + Zidovudine + Nevirapine is not recommended for HIV post-exposure prophylaxis (PEP) in HIV-negative individuals because of the risk of severe nevirapine-associated hepatotoxicity and skin reactions in this setting.
- Choice of regimen, including whether Lamivudine + Zidovudine + Nevirapine remains appropriate, should be individualized by a physician based on current national/WHO first-line ART recommendations, prior treatment history, and (where available) resistance testing.
Dosage & Administration of Lamivudine + Zidovudine + Nevirapine
Adult Dosing
| Step | Regimen |
|---|---|
| Lead-in period (first 14 days) | Nevirapine alone 200 mg once daily (using a separate nevirapine-only tablet), to reduce the risk of rash. Lamivudine + Zidovudine + Nevirapine fixed-dose tablets are not used during this lead-in period. |
| Maintenance (from day 15, if no rash/hepatotoxicity) | One Lamivudine + Zidovudine + Nevirapine tablet (typically lamivudine 150 mg + zidovudine 300 mg + nevirapine 200 mg) taken twice daily, approximately every 12 hours. |
Patients already established and tolerating nevirapine do not require a repeat lead-in when switching to Lamivudine + Zidovudine + Nevirapine. If a nevirapine dose is missed for more than 7 days, the lead-in dosing should generally be restarted under medical supervision.
Pediatric Dosing
Pediatric dosing of Lamivudine + Zidovudine + Nevirapine is weight-band based, using pediatric-strength scored or dispersible tablets of the same three-drug combination, following current WHO/national pediatric ART dosing charts. The adult-strength tablet must not be split or estimated for children; a formulation matched to the child's weight band must be used. See Pediatric Use.
Renal Impairment
Lamivudine and zidovudine both require dose reduction in renal impairment (creatinine clearance below 50 mL/min), but their doses cannot be adjusted independently within a fixed-dose tablet. Patients with significant renal impairment should generally not use the Lamivudine + Zidovudine + Nevirapine fixed-dose tablet and should instead receive the three components as separate, individually dosed medicines under physician supervision.
Hepatic Impairment
Lamivudine + Zidovudine + Nevirapine is contraindicated in moderate-to-severe hepatic impairment (see Contraindications). Mild hepatic impairment requires close clinical and laboratory monitoring.
Missed Dose
If a dose of Lamivudine + Zidovudine + Nevirapine is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped — never take a double dose. Consistent, on-time dosing is essential (see Precautions and Warnings).
Side Effects of Lamivudine + Zidovudine + Nevirapine
Side effects of Lamivudine + Zidovudine + Nevirapine reflect the combined profile of its three components.
| Category | Effects |
|---|---|
| Very common/common | Nausea, headache, fatigue, diarrhea, abdominal discomfort, and rash (usually mild-to-moderate) |
| Hematologic (zidovudine) | Anemia, neutropenia; rarely severe bone marrow suppression requiring transfusion or dose interruption |
| Hepatic (nevirapine) | Elevated liver enzymes; rarely severe, potentially fatal hepatotoxicity (see Precautions and Warnings) |
| Dermatologic (nevirapine) | Rash, and rarely severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (see Precautions and Warnings) |
| Metabolic/muscular | Lactic acidosis, hepatomegaly with steatosis (rare, NRTI class effect), lipodystrophy, and (with long-term zidovudine use) myopathy |
Patients should seek prompt medical attention for new rash, yellowing of the skin/eyes, unusual tiredness, easy bruising/bleeding, or signs of severe allergic reaction.
Contraindications of Lamivudine + Zidovudine + Nevirapine
Lamivudine + Zidovudine + Nevirapine is contraindicated in:
- Known hypersensitivity to lamivudine, zidovudine, nevirapine, or any component of the formulation.
- Moderate-to-severe hepatic impairment (Child-Pugh Class B or C), due to the nevirapine component.
- Prior discontinuation of nevirapine due to severe rash, hypersensitivity reaction, or nevirapine-associated hepatitis (must not be re-challenged).
- Co-administration with drugs highly dependent on CYP3A for clearance where increased or decreased plasma concentrations of either agent could cause serious or life-threatening effects.
Frequently Asked Questions about Lamivudine + Zidovudine + Nevirapine
What is Lamivudine + Zidovudine + Nevirapine used for?
Lamivudine + Zidovudine + Nevirapine is a fixed-dose combination antiretroviral tablet used to treat HIV-1 infection. It combines two NRTIs (lamivudine and zidovudine) with one NNRTI (nevirapine) into a complete, guideline-directed triple-drug ART regimen that suppresses HIV replication and helps preserve immune function.
How should I take Lamivudine + Zidovudine + Nevirapine?
Most adults take one Lamivudine + Zidovudine + Nevirapine tablet by mouth twice daily, approximately every 12 hours, usually after an initial 14-day period of nevirapine alone to reduce rash risk. Take it exactly as your physician prescribes, with or without food, at consistent times each day, and never skip, double up on, or stop doses without medical advice.
What are the most serious risks with Lamivudine + Zidovudine + Nevirapine?
The most serious risks with Lamivudine + Zidovudine + Nevirapine come mainly from its nevirapine component and include severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), especially in the first few weeks, and severe liver toxicity, especially in the first 18 weeks. Its zidovudine component can also cause bone marrow suppression (anemia, low white cell counts), and rarely, lactic acidosis can occur. Seek immediate medical attention for new rash, yellowing skin/eyes, unusual fatigue, or easy bruising.
Can Lamivudine + Zidovudine + Nevirapine be used during pregnancy or breastfeeding?
Lamivudine + Zidovudine + Nevirapine should be used in pregnancy only according to current national/WHO guideline-directed antiretroviral regimens, as decided by a physician, since the benefit of viral suppression and reducing transmission to the baby must be weighed against nevirapine-specific risks. Breastfeeding decisions should also follow current national/WHO guidance and be individualized with your physician, as all three components pass into breast milk. Never start, stop, or change Lamivudine + Zidovudine + Nevirapine during pregnancy or while breastfeeding without medical advice.
What happens if I miss a dose or stop taking Lamivudine + Zidovudine + Nevirapine?
Missing doses or stopping Lamivudine + Zidovudine + Nevirapine without medical advice risks the virus becoming active again and developing resistance to the medicine, which can make future treatment harder. If you miss a dose, take it as soon as you remember unless it is nearly time for the next dose — do not double up. If you need to stop treatment for any reason, talk to your physician first, since nevirapine's long half-life may require a specific stopping strategy to avoid resistance.
Can Lamivudine + Zidovudine + Nevirapine be given to children?
Yes, Lamivudine + Zidovudine + Nevirapine can be used in children using pediatric-strength formulations of the same three drugs, dosed by body weight according to national/WHO pediatric ART guidelines. The adult-strength tablet should never be split or estimated for a child; only a formulation matched to the child's weight should be used, and dosing should be supervised by a pediatric HIV specialist.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.